• Thu, Jan. 5, 3:37 PM
    • Barron's reports that Jefferies believes "only the strong (biotechs) will survive" this year. Despite strong underlying science, a more receptive regulatory environment and continued pricing power for innovative products, headwinds remain. The inability to aggressively hike prices for core franchises will place more of a premium on innovation and M&A to drive growth. Key picks:
    • Large cap: Celgene (CELG +0.2%), Gilead Sciences (GILD -0.5%).
    • Mid cap: Alkermes (ALKS -0.9%), Vertex Pharmaceuticals (VRTX +2.8%).
    • Small cap: Aevi Genomic Medicine (GNMX -0.2%), Alder BioPharmaceuticals (ALDR +2.2%), AMAG Pharmaceuticals (AMAG +3.5%), DBV Technologies (DBVT +1.1%), Immunomedics (IMMU), Ignyta (RXDX +10.8%), Karyopharm Therapeutics (KPTI +2.6%), Ra Pharmaceuticals (RARX +4.2%), TherapeuticsMD (TXMD -0.6%), Xenon Pharmaceuticals (XENE -1.9%).
    Thu, Jan. 5, 3:37 PM | 32 Comments
  • Nov. 9, 2016, 12:42 PM
    Nov. 9, 2016, 12:42 PM
  • Nov. 7, 2016, 4:11 PM
    • Karyopharm Therapeutics (NASDAQ:KPTI): Q3 EPS of -$0.69 beats by $0.12.
    • Revenue of $0.05M (-37.5% Y/Y) beats by $0.01M.
    • Press Release
    Nov. 7, 2016, 4:11 PM
  • Sep. 6, 2016, 12:45 PM
    Sep. 6, 2016, 12:45 PM
  • Sep. 6, 2016, 11:00 AM
    Sep. 6, 2016, 11:00 AM | 1 Comment
  • Sep. 6, 2016, 9:14 AM
    Sep. 6, 2016, 9:14 AM
  • Sep. 6, 2016, 8:33 AM
    • Karyopharm Therapeutics (NASDAQ:KPTI) is down 6% premarket on increased volume in response to its announcement of results from a Phase 2b clinical trial, STORM, assessing lead product candidate selinexor for the treatment of multiple myeloma (MM). The primary endpoint was overall response rate (ORR) over five-to-seven months.
    • The single-arm open-label study evaluated selinexor, in combination with low-dose dexamethasone, in heavily pretreated (not responding to other therapies) MM patients. The overall response rate (ORR) in 78 evaluable subjects (median of seven prior treatment regimens) was 20.5% (very good partial responders + partial responders). For comparison, the ORR for Janssen's (NYSE:JNJ) DARZALEX (daratumumab) in these types of patients was 20 - 21% while Sanofi's (NYSE:SNY) isatuximab showed 20%.
    • The safety profile was similar to earlier trials. Additional data will be presented later this year.
    • The company intends to expand STORM to include an additional 120 patients with penta-refractory (they basically haven't responded to anything) MM. Top-line data from the expanded cohort should be available in early 2018. The company plans to request accelerated approval by the FDA based on the results.
    • It also plans to initiate a pivotal 360-subject Phase 3 study, BOSTON, evaluating selinexor, in combination with Takeda's (OTCPK:TKPHF)(OTCPK:TKPYYVELCADE (bortezomib) and low-dose dexamethasone compared to VELCADE and low-dose dexamethasone alone in MM patients who have had one-to-three prior lines of therapy. The study should commence in early 2017.
    • Selinexor is a SINE (Selective Inhibitor of Nuclear Export) compound. It binds to and inhibits the nuclear export protein XPO1 which leads to the accumulation of tumor suppressor proteins in the cell nucleus which amplifies tumor suppression. It is also under development for the treatment of liposarcoma, diffuse large B-cell lymphoma and acute myeloid leukemia.
    • Management will host a conference call this morning at 8:30 am ET to discuss the data.
    • Previously: Karyopharm up 22%; selinexor data in multiple myeloma expected in September (Aug. 30)
    • Update: Slingshot Insights has an expert interview on deck to discuss the Phase 2 data.
    Sep. 6, 2016, 8:33 AM
  • Sep. 2, 2016, 5:35 PM
    • Top gainers, as of 5.25 p.m.: REN +3.2%. PNNT +2.7%. HPJ +2.5%. KPTI +1.7%. TEF +1.5%.
    • Top losers, as of 5.25p.m.: STM -5.0%. SXCP -3.3%. COTY -2.1%. ARWR -2.1%.
    Sep. 2, 2016, 5:35 PM | 5 Comments
  • Sep. 2, 2016, 12:32 PM
    Sep. 2, 2016, 12:32 PM
  • Sep. 2, 2016, 8:06 AM
    • Boston Scientific (NYSE:BSX) upgraded to Buy from Hold with a $33 (36% upside) price target by Argus Research.
    • Novo Nordisk (NYSE:NVO) upgraded to Hold from Reduce by HSBC.
    • Karyopharm (NASDAQ:KPTI) upgraded to Buy from Hold by Jefferies. Price target raised to $12 (8% upside) from $9.
    • AstraZeneca (NYSE:AZN) upgraded to Buy from Hold with a $38 (17% upside) price target by Argus Research.
    • Quest Diagnostics (NYSE:DGX) downgraded to Neutral from Buy with an $86 (4% upside) price target by Mizuho Securities.
    Sep. 2, 2016, 8:06 AM | 2 Comments
  • Aug. 30, 2016, 12:47 PM
    Aug. 30, 2016, 12:47 PM
  • Aug. 30, 2016, 11:01 AM
    Aug. 30, 2016, 11:01 AM | 1 Comment
  • Aug. 30, 2016, 10:48 AM
    • Thinly traded micro cap Karyopharm Therapeutics (KPTI +22.2%) heads north on more than a 4x surge in volume. No particular news accounts for the high volume action although investors may be starting to build positions ahead of the release of data from a Phase 2 clinical trial, STORM, assessing lead product candidate selinexor in treatment-resistant multiple myeloma. Top-line results should be available in September.
    • Selinexor is a SINE (Selective Inhibitor of Nuclear Export) compound. It binds to and inhibits the nuclear export protein XPO1 which leads to the accumulation of tumor suppressor proteins in the cell nucleus which amplifies tumor suppression. It is also under development for the treatment of liposarcoma, diffuse large B-cell lymphoma and acute myeloid leukemia.
    • Today, Jefferies upgraded to stock to Buy from Hold with a $12 (37% upside) price target based on the expectation of positive STORM results.
    Aug. 30, 2016, 10:48 AM
  • Aug. 19, 2016, 8:01 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $15 (112% upside) price target by Cantor Fitzgerald.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Buy rating and $15 (92% upside) price target by H.C. Wainwright.
    • Mediwound Ltd. (NASDAQ:MDWD) initiated with Outperform rating and $14 (75% upside) price target by Wells Fargo.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $15 (436% upside) price target by Guggenheim Securities.
    • Patheon NV (Pending:PTHN) initiated with Neutral rating and $30 (7% upside) price target by Credit Suisse. Initiated with Buy rating and $32 (14% upside) price target by Jefferies. Initiated with Overweight rating and $31 (11% upside) price target by Morgan Stanley.
    • GlycoMimetics (NASDAQ:GLYC) initiated with Outperform rating by Cowen and Company. Initiated with Outperform rating and $32.50 (306% upside) price target by Raymond James.
    • Audentes Therapeutics (Pending:BOLD) initiated with an Outperform rating by Cowen and Company. Initiated with Outperform rating and $20 (33% upside) price target by Wedbush.
    • Mallinckrodt (NYSE:MNK) initiated with Buy rating and $95 (19% upside) price target by Stifel Nicolaus.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $122 (28% upside) price target by RBC Capital.
    Aug. 19, 2016, 8:01 AM | 1 Comment
  • Aug. 18, 2016, 9:13 AM
    • Thinly traded micro cap Karyopharm Therapeutics (NASDAQ:KPTI) is up 7% premarket, albeit on only 5,650 shares. H.C. Wainwright initiated coverage with a Buy (what else) recommendation and $15 (100% upside) price target.
    Aug. 18, 2016, 9:13 AM
  • Aug. 4, 2016, 7:33 AM
    • Karyopharm Therapeutics (NASDAQ:KPTI): Q2 EPS of -$0.84 misses by $0.08.
    • Revenue of $0.06M (-60.0% Y/Y) beats by $0.02M.
    • Press Release
    Aug. 4, 2016, 7:33 AM